Status:
UNKNOWN
Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa
Lead Sponsor:
Aswan University Hospital
Conditions:
Placenta Previa
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
Purpose to evaluate the effects of Vaginal Progesterone versus 17-Alpha-Hydroxyprogesterone Caproate for prevention of Emergent Cesarean Delivery in Asymptomatic Pregnant Women with Placenta Previa
Detailed Description
The study will be a randomized open-label clinical trial conducted at a tertiary university hospital outpatient clinic and some private settings at Aswan governorate, Egypt, between January 2019 and M...
Eligibility Criteria
Inclusion
- Gestational age 26-28 weeks of gestation.
- Definite and reliable diagnosis of placenta previa (defined as the presence of a placenta within 2 cm of the internal os), using a transvaginal ultrasound scan
Exclusion
- Multiple pregnancies.
- Women at high risk of preterm labor e.g. history of spontaneous preterm labor or preterm prelabour rupture of the membranes (PPROM).
- Severe antepartum hemorrhage and/or hemodynamic instability that necessitates urgent -intervention and delivery.
- Women who have been maintained on progestin therapy since early pregnancy for whatever reason.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2022
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03779451
Start Date
January 1 2019
End Date
April 1 2022
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University
Aswān, Egypt, 81528